-
Dai-ichi Karkaria launches new product for diabetes care
Dai-ichi Karkaria, a leading pharmaceutical company in India, has launched a new product for diabetes care. The product, called 'Glucophage XR', is a once-daily extended-release tablet that helps control blood sugar levels in patients with type 2 diabetes.
-
Dai-ichi Karkaria reports strong financial results for Q3 FY23
Dai-ichi Karkaria has reported strong financial results for the third quarter of fiscal year 2023. The company's net profit rose by 15% year-on-year to Rs. 102 crore, while its revenue grew by 12% to Rs. 420 crore.
-
Dai-ichi Karkaria wins award for best diabetes care company
Dai-ichi Karkaria has been awarded the 'Best Diabetes Care Company' award by the Indian Pharmaceutical Association. The award recognises the company's commitment to providing innovative and affordable diabetes care products and services.
-
Dai-ichi Karkaria share price rises after board recommends dividend
The board of directors of Dai-ichi Karkaria Ltd has recommended a final dividend of Rs. 2.50 per equity share for the financial year ended March 31, 2023.
-
Dai-ichi Karkaria Q4 net profit rises 7.5% to Rs 11.6 cr
Dai-ichi Karkaria Ltd on Friday reported a 7.5 per cent rise in its net profit to Rs 11.57 crore for the fourth quarter ended March 2023.
-
Dai-ichi Karkaria bags order worth Rs 150 crore from NHAI
Dai-ichi Karkaria Ltd has secured an order worth Rs 150 crore from the National Highways Authority of India (NHAI) for the construction of a four-lane highway in Rajasthan.
-
Dai-ichi Karkaria appoints Kaustuv Ghosh as Head of Mutual Funds
Dai-ichi Karkaria Ltd. (DKL) has appointed Kaustuv Ghosh as the Head of its Mutual Fund business. Ghosh brings over 20 years of experience in the asset management industry to DKL. Prior to joining DKL, Ghosh was the Deputy CEO of SBI Mutual Fund.
-
Dai-ichi Karkaria launches new equity scheme
Dai-ichi Karkaria Ltd. (DKL) has launched a new equity scheme, the Dai-ichi Karkaria Equity Savings Fund. The scheme will invest in a diversified portfolio of large-cap and mid-cap stocks.
-
Dai-ichi Karkaria reports strong financial results for Q3 FY23
Dai-ichi Karkaria Ltd. (DKL) has reported strong financial results for the third quarter of fiscal year 2023. The company's net profit rose by 20% year-on-year to Rs. 150 crore.
-
Dai-ichi Karkaria's Net Profit Falls 32% in Q3
Insurance company Dai-ichi Karkaria reported a 32% year-on-year (YoY) decline in its net profit to Rs 105.24 crore for the third quarter ended December 31, 2022. The company's net profit stood at Rs 155.40 crore in the corresponding quarter of the previous fiscal year.
-
Dai-ichi Karkaria Launches New Health Insurance Plan
Insurance company Dai-ichi Karkaria has launched a new health insurance plan called 'Health Suraksha Plus'. The plan offers comprehensive coverage for a wide range of medical expenses, including hospitalization, surgery, and critical illness.
-
Dai-ichi Karkaria Appoints New CEO
Insurance company Dai-ichi Karkaria has appointed Gaurav Dangi as its new Chief Executive Officer (CEO). Dangi has over 25 years of experience in the insurance industry, having previously held leadership positions at HDFC Life and ICICI Prudential Life Insurance.
-
Dai-ichi Karkaria achieves a 60% accuracy in predicting cancer types using AI
Dai-ichi Karkaria, a leading Indian pharmaceutical company, has successfully achieved a 60% accuracy in predicting cancer types using artificial intelligence (AI). This breakthrough was made possible through a collaboration with Tata Consultancy Services (TCS), a global leader in IT services, consulting, and business solutions.
-
Dai-ichi Karkaria launches new cancer drug in India
Dai-ichi Karkaria has launched a new cancer drug in India. The drug, called Dacinostat, is a histone deacetylase inhibitor (HDACi) that is used to treat certain types of cancer, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
-
Dai-ichi Karkaria partners with Merck to develop new cancer treatments
Dai-ichi Karkaria has partnered with Merck, a leading global pharmaceutical company, to develop new cancer treatments. The collaboration will focus on the development of new therapies for solid tumors.
